文献速递肾小球疾病慢性肾脏病

狼疮性肾炎:重新定义治疗目标

Lupus nephritis: redefining the treatment goals.
PubMed 文献 · Kidney Int · 2024-11-08

本文讨论狼疮性肾炎疾病活动度的临床、血清学和组织学评估工具,指出传统以蛋白尿下降和肾功能改善判断疗效无法区分活动性炎症与慢性损伤。作者提出应同时追求三个治疗目标:临床缓解、免疫学缓解和肾功能保护,并建议用更动态个体化的方案替代传统诱导-维持方案。

要点

  • 传统疗效判断仅看蛋白尿和肾功能,无法区分活动性炎症与慢性损伤。
  • 临床缓解者重复肾活检仍可能见持续炎症,组织学缓解应成为治疗目标。
  • 建议同时追求临床缓解、免疫学缓解和肾功能保护三个目标。

核心结论

  • 持续免疫失调是狼疮性肾炎疾病活动的驱动因素,应作为治疗和监测的主要焦点。
  • 建议用更动态个体化的方案替代传统诱导-缓解维持方案,同时而非序贯追求三个治疗目标。

研究设计与样本

  • 本文为综述/观点类文章,讨论狼疮性肾炎疾病活动度评估工具及治疗目标重新定义。

主要发现

  • 传统以蛋白尿下降程度和肾功能改善判断治疗反应,但无法区分持续炎症与慢性损伤。
  • 尽管大量研究,尚无新型生物标志物被证明可用于临床实践,仍依赖抗双链DNA抗体水平评估血清学活动。
  • 重复肾活检有时在临床缓解者中仍显示持续炎症,支持组织学缓解应成为治疗目标。
  • 临床与组织学反应不一致可由持续系统性自身免疫伴低度免疫复合物沉积或免疫缓解后肾内炎症清除延迟解释。

关键数值与推荐

  • 临床缓解:以镜下血尿、蛋白尿、估算肾小球滤过率和补体水平为生物标志物,减轻肾脏炎症。
  • 免疫学缓解:以抗双链DNA抗体为生物标志物,减少免疫复合物生成。
  • 肾功能保护:以估算肾小球滤过率斜率为生物标志物,遏制慢性肾脏损伤。

临床怎么用

  • 评估狼疮性肾炎活动度时应综合临床、血清学和组织学工具,而非仅依赖蛋白尿和肾功能。
  • 考虑将组织学缓解作为治疗目标,方案性肾活检可参与决策过程。
  • 治疗和监测应以持续免疫失调为主要焦点,同时追求临床缓解、免疫学缓解和肾功能保护。

局限性

  • 尚无新型生物标志物被证明可用于临床实践,仍依赖抗双链DNA抗体评估血清学活动。
  • 临床与组织学反应不一致的机制解释尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The course of proliferative lupus nephritis is characterized by flares of activity alternating with periods of quiescence against a background of chronic immune dysregulation. An accurate assessment of disease activity is of unassailable importance to tailor therapy. In the present communication, we discuss the available clinical, serologic, and histologic tools to evaluate disease activity and how they may be applied to redefine the treatment goals in lupus nephritis. Traditionally, treatment response is judged by the degree of proteinuria reduction and improvement of kidney function, but this fails to differentiate ongoing inflammatory disease from chronic damage. Despite intensive research, no novel biomarker has proved useful for clinical practice, and we continue to rely on anti-double-stranded DNA antibody levels to assess serologic activity. Repeat kidney biopsies sometimes reveal persistent inflammation despite apparent clinical remission, giving credibility to the conviction that histologic remission should be a treatment goal and protocol biopsies be part of the decision-making process. However, the discrepancies between clinical and histologic responses to therapy can be explained by persistent systemic autoimmunity with low-grade immune complex deposition or, alternatively, by delayed clearance of intrarenal inflammation once immunologic remission has been achieved. Because persistent immune dysregulation is the motor of disease activity in lupus nephritis, it should be the principal focus of therapy and monitoring. We propose to replace the traditional induction-remission maintenance protocol by a more dynamic and individualized approach and aim for 3 treatment goals, concomitantly rather than sequentially: (i) clinical remission, by attenuating renal inflammation, using microscopic hematuria, proteinuria, estimated glomerular filtration rate, and complement levels as biomarkers; (ii) immunologic remission, by decreasing immune complex generation, using anti-double-stranded DNA antibody as a biomarker; and (iii) preservation of kidney function, by curtailing chronic kidney damage, using estimated glomerular filtration rate slope as a biomarker.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. De Vriese AS, Sethi S, Fervenza FC, et al. Lupus nephritis: redefining the treatment goals. Kidney Int. 2024. PMID: 39521057. doi:10.1016/j.kint.2024.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。